{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:50:09Z","timestamp":1792093809667,"version":"4.4.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FIS PI22\/01364"],"award-info":[{"award-number":["FIS PI22\/01364"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PMP22\/00021"],"award-info":[{"award-number":["PMP22\/00021"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP15\/00027"],"award-info":[{"award-number":["PMP15\/00027"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.beem.2024.101893","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T13:38:42Z","timestamp":1710855522000},"page":"101893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Predictors of biochemical response to somatostatin receptor ligands in acromegaly"],"prefix":"10.1016","volume":"38","author":[{"given":"M\u00f3nica","family":"Marazuela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Mart\u00ednez-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Marques-Pamies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101893_bib1","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101893_bib3","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101893_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.23736\/S0391-1977.18.02937-1","article-title":"Precision medicine in the treatment of acromegaly","volume":"44","author":"Puig-Domingo","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"G\u00fcnther","year":"2018","journal-title":"Pharm Rev"},{"key":"10.1016\/j.beem.2024.101893_bib8","first-page":"227","article-title":"Pasireotide: a novel treatment for patients with acromegaly","volume":"10","author":"Cuevas-Ramos","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.beem.2024.101893_bib9","article-title":"Resistance to Somatostatin analogs in Italian acromegaly patients: the MISS study","volume":"12","author":"Berton","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.beem.2024.101893_bib10","article-title":"Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study","volume":"67","author":"Durmu\u015f","year":"2022","journal-title":"Growth Horm IGF Res J Growth Horm Res Soc Int IGF Res Soc"},{"key":"10.1016\/j.beem.2024.101893_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib12","doi-asserted-by":"crossref","first-page":"dgaa387","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib13","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2024.101893_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.984877","article-title":"Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain","volume":"13","author":"Biagetti","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib15","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1210\/clinem\/dgad378","article-title":"Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.957301","article-title":"Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2265.1988.tb02890.x","article-title":"Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical \u201ccure","volume":"29","author":"Lamberts","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101893_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11102-005-1756-2","article-title":"Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve \u201csafe\u201d growth hormone levels","volume":"7","author":"Lindsay","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib20","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2004.02191.x","article-title":"The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib21","first-page":"227","article-title":"Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR","volume":"62","author":"Jenkins","year":"2004","journal-title":"Horm Res"},{"key":"10.1016\/j.beem.2024.101893_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2008-1065339","article-title":"A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients","volume":"40","author":"Halperin","year":"2008","journal-title":"Horm Metab Res Horm Stoffwechs Horm Metab"},{"key":"10.1016\/j.beem.2024.101893_bib23","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2265.2011.03982.x","article-title":"Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure","volume":"74","author":"Carlsen","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101893_bib24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ghir.2005.02.007","article-title":"Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly","volume":"15","author":"Biermasz","year":"2005","journal-title":"Growth Horm IGF Res J Growth Horm Res Soc Int IGF Res Soc"},{"key":"10.1016\/j.beem.2024.101893_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0022-3859.62421","article-title":"The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly","volume":"56","author":"Bandgar","year":"2010","journal-title":"J Post Med"},{"key":"10.1016\/j.beem.2024.101893_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1507\/endocrj.EJ16-0175","article-title":"The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly","volume":"63","author":"Wang","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2024.101893_bib27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1590\/S0004-27302005000300010","article-title":"Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR","volume":"49","author":"Taboada","year":"2005","journal-title":"Arq Bras Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1590\/S0004-27302004000200007","article-title":"Usefulness of subcutaneous or long-acting octreotide as a predictive test and in the treatment of acromegaly","volume":"48","author":"Halah","year":"2004","journal-title":"Arq Bras Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib29","first-page":"700","article-title":"Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests","volume":"85","author":"Schmidt","year":"1990","journal-title":"Med Klin Munich Ger 1983"},{"key":"10.1016\/j.beem.2024.101893_bib30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2265.2005.02278.x","article-title":"The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly","volume":"62","author":"Gilbert","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101893_bib31","first-page":"2356","article-title":"Prediction of efficacy of octreotide therapy in patients with acromegaly","volume":"81","author":"Colao","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.1.01935","article-title":"Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly","volume":"153","author":"de Herder","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/eje.1.02073","article-title":"The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly","volume":"154","author":"Pokrajac","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1269787","article-title":"Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly","volume":"14","author":"Marques-Pamies","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the Personalized Treatment of Acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib36","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00234-016-1728-4","article-title":"Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly","volume":"58","author":"Shen","year":"2016","journal-title":"Neuroradiology"},{"key":"10.1016\/j.beem.2024.101893_bib37","article-title":"Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: a hospital-based study of 237 cases","volume":"55","author":"Shen","year":"2020","journal-title":"Growth Horm IGF Res J Growth Horm Res Soc Int IGF Res Soc"},{"key":"10.1016\/j.beem.2024.101893_bib38","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1507\/endocrj.53.125","article-title":"Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage","volume":"53","author":"Oshino","year":"2006","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2024.101893_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.935759","article-title":"Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis","volume":"13","author":"Mondin","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib42","first-page":"1416","article-title":"Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy","volume":"79","author":"Pl\u00f6ckinger","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib43","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/BF03347995","article-title":"111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients","volume":"20","author":"Legovini","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101893_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2265.1997.3361119.x","article-title":"Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide","volume":"47","author":"Broson-Chazot","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101893_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF01390518","article-title":"Somatostatin receptor scintigraphy in patients with pituitary adenoma","volume":"20","author":"Rieger","year":"1997","journal-title":"Neurosurg Rev"},{"key":"10.1016\/j.beem.2024.101893_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF03343538","article-title":"The pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas","volume":"22","author":"Colao","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101893_bib47","first-page":"117","article-title":"Prediction of the pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index","volume":"36","author":"G\u00f6rges","year":"1997","journal-title":"NuklearMedizin"},{"key":"10.1016\/j.beem.2024.101893_bib48","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s40618-021-01523-6","article-title":"Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly","volume":"44","author":"Daniel","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101893_bib49","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib50","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.beem.2024.101893_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101893_bib52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101893_bib53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib54","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.21037\/gs.2019.06.04","article-title":"Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas","volume":"8","author":"Tortora","year":"2019","journal-title":"Gland Surg"},{"key":"10.1016\/j.beem.2024.101893_bib55","first-page":"425","article-title":"The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI","volume":"94","author":"Sc\u00e2nteie","year":"2021","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.beem.2024.101893_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib57","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly-a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib58","first-page":"835","article-title":"Added value of dynamic contrast-enhanced magnetic resonance imaging in predicting response to somatostatin analogs in acromegaly patients","volume":"29","author":"Durmaz","year":"2019","journal-title":"Turk Neurosurg"},{"key":"10.1016\/j.beem.2024.101893_bib59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib60","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.beem.2024.101893_bib61","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/cen.14946","article-title":"Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly","volume":"99","author":"Ruiz","year":"2023","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib62","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4158\/EP-2018-0500","article-title":"Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline","volume":"25","author":"Ezzat","year":"2019","journal-title":"Endocr Pr"},{"key":"10.1016\/j.beem.2024.101893_bib63","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12020-023-03317-7","article-title":"Modern approach to resistant acromegaly","volume":"80","author":"Giustina","year":"2023","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101893_bib64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11102-017-0788-8","article-title":"T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective","volume":"20","author":"Potorac","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11102-019-01023-0","article-title":"MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands","volume":"23","author":"Galm","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11102-020-01077-5","article-title":"Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas","volume":"23","author":"Park","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib67","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20220401","article-title":"Quality reporting of radiomics analysis in pituitary adenomas: promoting clinical translation","volume":"95","author":"Won","year":"2022","journal-title":"Br J Radio"},{"key":"10.1016\/j.beem.2024.101893_bib68","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radio"},{"key":"10.1016\/j.beem.2024.101893_bib69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.47162\/RJME.64.1.03","article-title":"Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review","volume":"64","author":"Gliga","year":"2023","journal-title":"Rom J Morphol Embryol Rev Roum Morphol Embryol"},{"key":"10.1016\/j.beem.2024.101893_bib70","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib71","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jcmm.13440","article-title":"Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly","volume":"22","author":"Venegas-Moreno","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.beem.2024.101893_bib72","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101893_bib73","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1210\/jc.2007-1986","article-title":"Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas","volume":"93","author":"Pl\u00f6ckinger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib74","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib75","first-page":"1","article-title":"Expression of Somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101893_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib78","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib79","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","author":"Casarini","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib80","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib81","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib82","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1210\/jc.2018-01524","article-title":"Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression","volume":"104","author":"Muhammad","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib83","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"MAnagement of endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib85","first-page":"1050","article-title":"Somatostatin receptor subtype expression in patients with acromegaly and complicated clinical course","volume":"11","author":"Pichler","year":"2021","journal-title":"Diagn Basel Switz"},{"key":"10.1016\/j.beem.2024.101893_bib86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s42000-021-00327-w","article-title":"Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?","volume":"21","author":"Rass","year":"2022","journal-title":"Horm Athens Greece"},{"key":"10.1016\/j.beem.2024.101893_bib87","first-page":"20","article-title":"Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology","volume":"33","author":"Yamada","year":"1993","journal-title":"Neurosurgery"},{"key":"10.1016\/j.beem.2024.101893_bib88","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-10-0586","article-title":"Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae","volume":"163","author":"Bakhtiar","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","article-title":"Growth hormone tumor histological subtypes predict response to surgical and medical therapy","volume":"49","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2024.101893_bib90","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib91","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.beem.2024.101893_bib92","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.beem.2024.101893_bib93","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-Cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib94","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib95","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/biomedicines10020460","article-title":"Implications of heterogeneity of epithelial-mesenchymal states in acromegaly therapeutic pharmacologic response","volume":"10","author":"Gil","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.beem.2024.101893_bib96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35000034","article-title":"The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells","volume":"2","author":"Batlle","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.beem.2024.101893_bib97","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib98","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1210\/en.2013-1672","article-title":"\u03b2-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly","volume":"154","author":"Gatto","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2024.101893_bib99","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib100","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1111\/jcmm.13427","article-title":"Molecular evidence and clinical importance of \u03b2\u2010arrestins expression in patients with acromegaly","volume":"22","author":"Coelho","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.beem.2024.101893_bib101","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1210\/jcem-71-6-1421","article-title":"Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase","volume":"71","author":"Spada","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib103","first-page":"1604","article-title":"Pronostic and therapeutic consequences of G(s)\u03b1 mutations in somatotroph adenomas","volume":"83","author":"Barlier","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib104","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.3390\/cancers13194857","article-title":"gsp mutation is not a molecular biomarker of long-term response to first-generation somatostatin receptor ligands in acromegaly","volume":"13","author":"Wildemberg","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.beem.2024.101893_bib105","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/17446651.2020.1749048","article-title":"Potential markers of disease behavior in acromegaly and gigantism","volume":"15","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib106","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2024.101893_bib107","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2024.101893_bib108","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/clinem\/dgac610","article-title":"Survivin: a potential marker of resistance to somatostatin receptor ligands","volume":"108","author":"Herkenhoff","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib109","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.3390\/ijms24032875","article-title":"miR-383-5p, miR-181a-5p, and miR-181b-5p as predictors of response to first-generation somatostatin receptor ligands in acromegaly","volume":"24","author":"Henriques","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beem.2024.101893_bib110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40618-018-0988-8","article-title":"GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly","volume":"42","author":"Ferra\u00f9","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2024.101893_bib111","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1210\/jc.2008-0126","article-title":"Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas","volume":"93","author":"Fusco","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101893_bib112","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1210\/en.2014-1063","article-title":"Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells","volume":"155","author":"Peverelli","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2024.101893_bib113","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41598-018-37692-3","article-title":"Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles","volume":"9","author":"Coelho","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2024.101893_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111159","article-title":"Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells","volume":"524","author":"Treppiedi","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.beem.2024.101893_bib115","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11102-022-01216-0","article-title":"Machine learning as a clinical decision support tool for patients with acromegaly","volume":"25","author":"Sulu","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2024.101893_bib116","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.3390\/cells11233846","article-title":"Transcriptomic classification of pituitary neuroendocrine tumors causing acromegaly","volume":"11","author":"Rymuza","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.beem.2024.101893_bib117","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresbull.2020.04.018","article-title":"Comprehensive circular RNA profiling reveals that hsa_circ_0001368 is involved in growth hormone-secreting pituitary adenoma development","volume":"161","author":"Du","year":"2020","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.beem.2024.101893_bib118","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/ijms23031413","article-title":"Rno_circ_0001004 acts as a miR-709 molecular sponge to regulate the growth hormone synthesis and cell proliferation","volume":"23","author":"Xiong","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beem.2024.101893_bib119","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1159\/000531200","article-title":"Clinical and proteomic-based molecular characterizations of invasive and noninvasive Somatotroph PitNETs","volume":"113","author":"Chen","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.beem.2024.101893_bib120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13167-021-00232-7","article-title":"Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches","volume":"12","author":"Li","year":"2021","journal-title":"EPMA J"},{"key":"10.1016\/j.beem.2024.101893_bib121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beem.2024.101893_bib122","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s42003-022-04272-1","article-title":"Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas\/somatotroph pituitary neuroendocrine tumors","volume":"5","author":"Yamato","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.beem.2024.101893_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.784819","article-title":"The application of artificial intelligence and machine learning in pituitary adenomas","volume":"11","author":"Dai","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.beem.2024.101893_bib124","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13167-021-00246-1","article-title":"Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies","volume":"12","author":"Aydin","year":"2021","journal-title":"EPMA J"},{"key":"10.1016\/j.beem.2024.101893_bib125","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1530\/EC-19-0156","article-title":"A systematic review on machine learning in sellar region diseases: quality and reporting items","volume":"8","author":"Qiao","year":"2019","journal-title":"Endocr Connect"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T18:48:30Z","timestamp":1721328510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1521690X24000472"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101893","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101893"}}